The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanders, M. E.
Right arrow Articles by Joiner, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanders, M. E.
Right arrow Articles by Joiner, K. A.

The Journal of Immunology, Vol 136, Issue 12 4456-4459, Copyright © 1986 by American Association of Immunologists

ARTICLES

Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis

ME Sanders, CL Koski, D Robbins, ML Shin, MM Frank and KA Joiner

A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 micrograms/ml; range, 0 to 7.1 micrograms/ml) and 16 of 21 patients with MS (mean, 1.83 micrograms/ml; range, 0 to 7.5 micrograms/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 micrograms/ml; range, 0 to 1.7 micrograms/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue- damaging processes in these diseases.


This article has been cited by other articles:


Home page
 BrainHome page
S. K. Halstead, F. M. P. Zitman, P. D. Humphreys, K. Greenshields, J. J. Verschuuren, B. C. Jacobs, R. P. Rother, J. J. Plomp, and H. J. Willison
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model
Brain, May 1, 2008; 131(5): 1197 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Geleijns, A. Roos, J. J. Houwing-Duistermaat, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, P. A. van Doorn, and B. C. Jacobs
Mannose-Binding Lectin Contributes to the Severity of Guillain-Barre Syndrome
J. Immunol., September 15, 2006; 177(6): 4211 - 4217.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
N. Natarajan and R. Weinstein
Therapeutic Apheresis in Neurology Critical Care
J Intensive Care Med, July 1, 2005; 20(4): 212 - 225.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
P. P. Ho, P. Fontoura, P. J. Ruiz, L. Steinman, and H. Garren
An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems
J. Immunol., November 1, 2003; 171(9): 4920 - 4926.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Wanschitz, H. Maier, H. Lassmann, H. Budka, and T. Berger
Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome
Brain, September 1, 2003; 126(9): 2034 - 2042.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K.H. Wollinsky, P.-J. Hulser, H. Brinkmeier, P. Aulkemeyer, W. Bossenecker, K.-H. Huber-Hartmann, P. Rohrbach, H. Schreiber, F. Weber, M. Kron, et al.
CSF filtration is an effective treatment of Guillain-Barre syndrome: A randomized clinical trial
Neurology, September 11, 2001; 57(5): 774 - 780.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Soane, H.-J. Cho, F. Niculescu, H. Rus, and M. L. Shin
C5b-9 Terminal Complement Complex Protects Oligodendrocytes from Death by Regulating Bad Through Phosphatidylinositol 3-Kinase/Akt Pathway
J. Immunol., August 15, 2001; 167(4): 2305 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Soane, H. Rus, F. Niculescu, and M. L. Shin
Inhibition of Oligodendrocyte Apoptosis by Sublytic C5b-9 Is Associated with Enhanced Synthesis of Bcl-2 and Mediated by Inhibition of Caspase-3 Activation
J. Immunol., December 1, 1999; 163(11): 6132 - 6138.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. C. Badea, F. I. Niculescu, L. Soane, M. L. Shin, and H. Rus
Molecular Cloning and Characterization of RGC-32, a Novel Gene Induced by Complement Activation in Oligodendrocytes
J. Biol. Chem., October 9, 1998; 273(41): 26977 - 26981.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F. Sellebjerg, M. Christiansen, and P. Garred
MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis
Multiple Sclerosis, June 1, 1998; 4(3): 127 - 131.
[Abstract] [PDF]

Home page
 Pharmacol. Rev.Home page
S. C. Makrides
Therapeutic Inhibition of the Complement System
Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.